| Date |
Title |
| Dec 17, 2019 |
Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study |
|
| Dec 03, 2019 |
Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment |
|
| Nov 12, 2019 |
Pluristem Therapeutics CEO Issues Shareholder Update |
|
| Nov 04, 2019 |
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare |
|
| Sep 16, 2019 |
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs |
|
| Sep 16, 2019 |
פלוריסטם מסכמת שיח מומחים על התוכניות בתחום ההמטולוגיה והטיפול בקרינה |
|
| Sep 09, 2019 |
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Programs |
|
| Aug 21, 2019 |
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs |
|
| Jul 31, 2019 |
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome |
|
| Jul 24, 2019 |
Pluristem Therapeutics’ CEO Issues Shareholders Update |
|
| Jul 24, 2019 |
Pluristem Announces One-for-Ten Reverse Split of its Common Shares |
|
| Jul 17, 2019 |
Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN |
|
| Jul 02, 2019 |
Pluristem Therapeutics’ CEO Issues Shareholder Letter |
|
| Jun 24, 2019 |
Pluristem Completes Transition Period of Co-CEO Structure – Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board |
|
| Jun 17, 2019 |
Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product |
|
| May 15, 2019 |
Lead Physicians in Pluristem’s Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper |
|
| May 06, 2019 |
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry |
|
| Apr 29, 2019 |
Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe |
|
| Apr 23, 2019 |
Pluristem Therapeutics Issues Shareholder Update |
|
| Apr 04, 2019 |
Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million |
|
| Apr 03, 2019 |
Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock |
|
| Mar 12, 2019 |
Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18 |
|
| Feb 20, 2019 |
Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions |
|
| Feb 11, 2019 |
RESTORE Consortium, of which Pluristem is a member, Nominated to Be One of Two Finalists Competing for a Potential Award for Development of Advanced Therapeutics |
|
| Jan 22, 2019 |
Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries |
|
| Jan 09, 2019 |
Pluristem Therapeutics Reports Successful Case Study in Treatment of Buerger’s Disease Patient |
|
| Jan 03, 2019 |
Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome |
|
